News Content
Its most mature research direction is **sleep disorder intervention**. As a peptide secreted by the body itself, it can precisely promote delta-wave sleep (deep sleep). Clinical data shows that in patients with primary insomnia, intravenous injection or nasal spray administration resulted in an average 28% reduction in sleep onset time and a 35% increase in deep sleep duration, without the side effects of benzodiazepines such as next-day drowsiness and dependence, making it particularly suitable for the elderly or drug-sensitive populations.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-dsip-2mg.html
Recent studies have discovered its **potential for stress regulation and pain management**. Under stress, DSIP can inhibit excessive activation of the hypothalamus-pituitary-adrenal axis, reducing cortisol levels by 20%-30% and alleviating stress responses such as anxiety and fatigue. In the field of chronic pain, it can enhance the analgesic effect of opioids, reduce drug dosage by approximately 40%, and lower the risk of addiction. These findings have been preliminarily validated in postoperative pain management trials.
It is important to note that DSIP is currently mostly in the clinical research stage, and only some countries have approved its use for the treatment of specific sleep disorders. Individual differences are also significant; approximately 12% of users report experiencing mild dizziness and fluctuations in appetite. Neurologists emphasize that "its advantage lies in 'physiological regulation,' but precise dosing regimens must be matched to individual needs to avoid indiscriminate use."
